ImmunoMet Lands $5,200,000 Series A Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    2450 Holcombe Blvd. Houston, TX 77021 USA
  • Company Description
    ImmunoMet Therapeutics is a development-stage biotechnology company, focused on the development of innovative oncology products to improve the quality of life and make a meaningful difference in the lives of cancer patients.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The primary use of these proceeds will be to fund the Company’s research and clinical development programs, establish its worldwide headquarters in Houston, TX, and for general corporate purposes.
  • M&A Terms
  • Venture Investor
    Mirae Asset Venture Investment
  • Venture Investor

Trending on Xconomy